Cost-effectiveness of implantable cardioverter defibrillators relative to amiodarone for prevention of sudden cardiac death

Annals of Internal Medicine

Volumn 126, Issue 1, 1997, Pages 1-12

  Owens, Douglas K ^b   Sanders, Gillian D ^b   Harris, Ryan A ^a   McDonald, Kathryn M ^a   Heidenreich, Paul A ^b   Dembitzer, Anne D ^b   Hlatky, Mark A ^a  

^a STANFORD UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART DEATH; HIGH RISK POPULATION; HUMAN; MORTALITY; PRIORITY JOURNAL; PROBABILITY; QUALITY OF LIFE; SUDDEN DEATH;

EID: 0031028592     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-1-199701010-00001     Document Type: Article

References (83)

1. National Center for Health Statistics. Advance report of final mortality. Monthly Vital Statistic Report. 1993;41:1-52.
2. Gillum RF. Sudden coronary death in the United States: 1980-1985. Circulation. 1989;79:756-65.
3. Schatzkin A, Cupples LA, Heeren T, Morelock S, Mucatel M, Kannel WB. The epidemiology of sudden unexpected death: risk factors for men and women in the Framingham Heart Study. Am Heart J. 1984;107:1300-6.
4. Pinski SL, Trohman RG. Implantable cardioverter-defibrillators: implications for the nonelectrophysiologist. Ann Intern Med. 1995;122:770-7.
5. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA. 1993;270:1589-95.
6. Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC. Efficacy and safety of quintdine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized controlled trials. Circulation. 1990;82: 1106-16.
7. Hine LK, Laird NM, Hewitt P, Chalmers TC. Meta-analysis of empirical long-term antiarrhythmic therapy after myocardial infarction. JAMA. 1989;262:3037-40.
8. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260:2088-93.
9. Echt DS, Liebson PR, Mitchell LB, Peters RW, Obias-Manno D, Barker AH, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med. 1991; 324:781-8.
10. Randomized antiarrhythmic drug therapy in survivors of cardiac arrest (the CASCADE Study). The CASCADE Investigators. Am J Cardiol. 1993;72:280-7.
11. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, Kuch J, Nartowicz E, Smielak-Korombel J, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. J Am Coil Cardiol. 1992;20:1056-62.
12. Cairns JA, Connolly SJ, Gent M, Roberts R. Post-myocardial infarction mortality in patients with ventricular premature depolarizations. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Pilot Study. Circulation. 1991;84:550-7.
13. Pfisterer ME, Kiowski W, Brunner H, Burckhardt D, Burkart F. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation. 1993;87:309-11.
14. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol. 1990;16:1711-8.
15. Mason JW. Amiodarone. N Engl J Med. 1987;316:455-66.
16. Podrid PJ. Amiodarone: reevaluation of an old drug. Ann Intern Med. 1995; 122:689-700.
17. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. PCD Investigator Group. J Am Coll Cardiol. 1994;23:1521-30.
18. Powell AC, Fuchs T, Finkelstein DM, Garan H, Can nom DS, McGovern BA, et al. Influence of implantable cardioverter-defibrillators on the long-term prognosis of survivors of out-of-hospital cardiac arrest. Circulation. 1993;88:1083-92.
19. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. Preliminary results of The Cardiac Arrest Study Hamburg (CASH). CASH Investigators. Am J Cardiol. 1993;72:109F-13F.
20. Siebels J, Kuck KH. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg). Am Heart J. 1994;127:1139-44.
21. Connolly SJ, Yusuf S. Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials [Editorial]. Am J Cardiol. 1992;69:959-62.
22. The Coronary Artery Bypass Graft (CABG) Patch Trial. The CABG Patch Trial Investigators and Coordinators. Prog Cardiovasc Dis. 1993;36:97-114.
23. Cardiomyopathy Trial. The Cardiomyopathy Trial Investigators. Pacing Clin Electrophysiol. 1993;16:576-81.
24. Actuarial risk of sudden death while awaiting cardiac transplantation in patients with atherosclerotic heart disease. DEFIBRILAT Study Group. Am J Cardiol. 1991;68:545-6.
25. Multicenter automatic defibrillator implantation trial (MADIT): design and clinical protocol. MADIT Executive Committee, Pacing Clin Electrophysiol. 1991; 14:920-7.
26. Antiarrhythmics Versus Implantable Defibrillators (AVID) - rationale, design, and methods. Am J Cardiol. 1995;75:470-5.
27. Connolly SJ, Gent M, Roberts RS, Dorian P, Green MS, Klein GJ, et al. Canadian Implantable Defibrillator Study (CIDS): study design and organization. CIDS Co-Investigators. Am J Cardiol. 1993;72:103F-8F.
28. Kuppermann M, Luce BR, McGovern B, Podrid PJ, Bigger JT Jr, Ruskin JN. An analysis of the cost effectiveness of the implantable defibrillator. Circulation. 1990;81:91-100.
29. O'Donoghue S, Platia EV, Brooks-Robinson S, Mispireta L. Automatic implantable cardioverter-defibrillator: is early implantation cost-effective? J Am Coll Cardiol. 1990;16:1258-63.
30. Larsen GC, Manolis AS, Sonnenberg FA, Beshansky JR, Estes NA, Pauker SG. Cost-effectiveness of the implantable cardioverter-defibrillator: effect of improved battery life and comparison with amiodarone therapy. J Am Coll Cardiol. 1992;19:1323-34.
31. Kupersmith J, Hogan A, Guerrero P, Gardiner J, Mellits ED, Baumgardner R, et al. Evaluating and improving the cost-effectiveness of the implantable cardiovener-defibrillator. Am Heart J. 1995;130:507-15.
32. Wever EF, Hauer RN, Schrijvers G, van Capelle FJ, Tijssen JG, Crijns HJ, et al. Cost-effectiveness of implantable defibrillator as first-choice therapy versus electrophysiologically guided, tiered strategy in postinfarct sudden death survivors. A randomized study. Circulation. 1996;93:489-96.
33. Lipscomb J, Weinstein MC, Torrance GW. In: Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-Effectiveness in Health and Medicine. New York: Oxford Univ Pr; 1996:214-46.
34. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making. 1983;3:419-58.
35. Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med Decis Making. 1993;13:322-38.
36. Sauve MJ, Doolittle N, Walker JA, Massa S. Cognitive recovery in sudden cardiac death survivors: a longitudinal study [Abstract]. Circulation. 1994; 90(S1):1-379.
37. Sauve MJ. Long term physical functioning and psychosocial adjustment in survivors of sudden cardiac death. Heart Lung. 1995;24:133-44.
38. Sauve MJ, Doolittle N, Walker JA, Paul SM, Scheinman MM. Factors associated with cognitive recovery after cardiopulmonary resuscitation. Am J Crit Care. 1996;5:127-39.
39. Fryback DG, Dasbach EJ, Klein R, Klein BE, Dorn N, Peterson K, et al. The Beaver Dam Health Outcomes Study: initial catalog of health-state quality factors. Med Decis Making. 1993;13:89-102.
40. Sox HC Jr, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston: Butterworth; 1988.
41. Owens DK, Sox HC Jr. Medical decision making: probabilistic medical reasoning. In: Shortliffe EH, Perreault LE, Wiederhold G, Fagan LM, eds. Medical Informatics: Computer Applications in Health Care. Reading, MA: Addison-Westey; 1990:70-116.
42. Siebels J, Cappato R, Ruppel R, Schneider MA, Kuck KH. ICD versus drugs in cardiac arrest survivors: preliminary results of the Cardiac Arrest Study Hamburg. Pacing Clin Electrophysiol. 1993;16:552-8.
43. Tchou PJ, Kadri N, Anderson J, Caceres JA, Jazayeri M, Akhtar M. Automatic implantable cardioverter defibrillators and survival of patients with left ventricular dysfunction and malignant ventricular arrhythmias. Ann Intern Med. 1988;109:529-34.
44. Fogoros RN, Elson JJ, Bonnet CA, Fiedler SB, Burkholder JA. Efficacy of the automatic implantable cardioverter-defibrillator in prolonging survival in patients with severe underlying cardiac disease. J Am Coll Cardiol. 1990;16: 381-6.
45. Newman D, Sauve MJ, Herre J, Langberg JJ, Lee MA, Titus C, et al. Survival after implantation of the cardioverter defibrillator. Am J Cardiol. 1992;69:899-903.
46. Böcker D, Block M, Isbruch F, Wietholt D, Hammel D, Borggrefe M, et al. Do patients with an implantable defibrillator live longer? J Am Coll Cardiol. 1993;21:1638-44.
47. Zipes DP, Roberts D. Results of the international study of the implantable pacemaker cardioverter-defibrillator. A comparison of epicardial and endocardial lead systems. The Pacemaker-Cardioverter-Defibrillator Investigators. Circulation. 1995;92:59-65.
48. Kleman JM, Castle LW, Kidwell GA, Maloney JD, Morant VA, Trohman RG, et al. Nonthoracotomy- versus thoracotomy-implantable defibrillators. Intention-to-treat comparison of clinical outcomes. Circulation. 1994; 90:2833-42.
49. Wever EF, Hauer RN, van Capelle FL, Tijssen JG, Crijns HJ, Algra A, et al. Randomized study of implantable defibrillator as first-choice therapy versus conventional strategy in postinfarct sudden death survivors. Circulation. 1995;91:2195-203.
50. Saksena S, Poczobutt-Johanos M, Castle LW, Fogoros RN, Alpert BL, Kron J, et al. Long-term multicenter experience with a second-generation implantable pacemaker-defibrillator in patients with malignant ventricular tachyarrhythmias. The Guardian Multicenter Investigators Group. J Am Coll Cardiol 1992;19:490-9.
51. Gabry MD, Brodman R, Johnston D, Frame R, Kim SG, Waspe LE, et al. Automatic implantable cardioverter-defibrillator: patient survival, battery longevity and shock delivery analysis. J Am Coll Cardiol. 1987;9:1349-56.
52. Longstreth WT Jr. Prediction of awakening after out-of-hospital cardiac arrest. N Engl J Med. 1983;308:1378-82.
53. Kolar JA, Dracup K. Psychosocial adjustment of patients with ventricular dysrhythmias. J Cardiovasc Nurs. 1990;4:44-55.
54. Nunain SO, Roelke M, Trouton T, Osswald S, Kim YH, Sosa-Suarez G, et al. Limitations and late complications of third-generation automatic cardioverter-defibrillators. Circulation. 1995;91:2204-13.
55. Korte T, Jung W, Spehl S, Wolpert C, Moosdorf R, Manz M, et al. Incidence of ICD lead related complications during long-term follow-up: comparison of epicardial and endocardial electrode systems. Pacing Clin Electrophysiol. 1995;18:2053-61.
56. Doval HC, Nul DR, Grancelli HO, Perrone SV, Sortman GR. Curiel R, et al. Randomised trial of tow-dose amiodarone in severe congestive heart failure. Grupo de Estudio de ta Sobrevida en la Insuficienoa Cardiaca en Argentina (GESICA). Lancet 1994;344:493-8.
57. Singh SN, Fletcher RD, Fisher SG, Singh BN, Lewis HD, Deedwania PC, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1995;333:77-82.
58. Herre JM, Sauve MJ, Malone P, Griffin JC, Helmy I, Langberg JJ. et al. Long-term results of amiodarone therapy in patients with recurrent sustained ventricular tachycardia or ventricular fibrillation. J Am Coll Cardiol. 1989;13: 442-9.
59. Hamer AW, Arkles B, Johns JA. Beneficial effects of low dose amiodarone in patients with congestive cardiac failure: a placebo-controlled trial. J Am Coll Cardiol. 1989;14:1768-74.
60. Nicklas JM, McKenna WJ, Stewart RA, Mickeison JK, Das SK, Schork MA, et al. Prospective, double-blind, placebo-controlled trial of low-dose amiodarone in patients with severe heart failure and asymptomatic frequent ventricular ectopy. Am Heart J. 1991;122(4 Pt 1):1016-21.
61. Singh SN, Fletcher RD, Fisher S, Lazzeri D, Deedwania P, Lewis D, et al. Veterans Affairs congestive heart failure antiarrhythmic trial. CHF STAT Investigators. Am J Cardiol. 1993;72:99F-102F.
62. Navarro-Lopez F, Cosin J, Marrugat J, Guindo J, Bayes de Luna A. Comparison of the effects of amiodarone versus metoprolol on the frequency of ventricular arrhythmias and on mortality after acute myocardial infarction. SSSD Investigators. Am J Cardiol. 1993;72:1243-8.
63. Camm AJ, Julian D, Janse G, Munoz A, Schwartz P, Simon P, et al. The European Myocardial Infarct Amiodarone Trial (EMIAT). EMIAT Investigators. Am J Cardiol. 1993;72:95F-8F.
64. Weinberg BA, Miles WM, Klein LS, Bolander JE, Dusman RE, Stanton MS, et al. Five-year follow-up of 589 patients treated with amiodarone. Am Heart J. 1993;125:109-20.
65. 1995 Redbook Update. Montvale, NJ: Medical Economics; 1995.
66. U.S. Preventive Services Task Force. Guide to Clinical Preventive Services: Report of the U.S. Preventive Services Task Force. 2d ed. Baltimore: Williams & Wilkins; 1996.
67. Kim SG, Maloney JD, Pinski SL, Choue CW, Ferrick KJ, Roth JA, et al. Influence of left ventricular function on survival and mode of death after implantable defibrillator therapy (Cleveland Clinic Foundation and Montefiore Medical Center experience). Am J Cardiol. 1993;72:1263-7.
68. Kim SG. Implantable defibrillator therapy: does it really prolong life? How can we prove it? [Editorial] Am J Cardiol. 1993;71:1213-8.
69. Kim SG, Fisher JD, Furman S. Hypothetical death rates of patients with implantable defibrillators remain very hypothetical [Editorial]. Am J Cardiol. 1993;72:1453-5.
70. Kim SG, Roth JA, Fisher JD, Chung J, Nagabhairu R, Ferrick KJ, et al. Long-term outcomes and modes of death of patients treated with nonthoracotomy implantable defibrillators. Am J Cardiol. 1995;75:1229-32.
71. Greene HL. Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study. Am Heart J. 1993;127:1171-8.
72. Bakker PF, Hauer RN, Wever EF. Infections involving implanted cardioverter defibrillator devices. Pacing Clin Electrophysiol. 1992;15:654-8.
73. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325:293-302.
74. Shannon JA, Hammill SC, Gersh BJ. Predictive value of early electrophysiologic testing in determining long-term outcome with amiodarone treatment in patients with sustained ventricular tachycardia. Mayo Clin Proc. 1991;66: 1114-9.
75. Multicentrc randomized trial of sotalol vs amiodarone for chronic malignant ventricular tachyarrhythmias. Amiodarone vs Sotalol Study Group. Eur Heart J. 1989;10:685-94.
76. Cardiac Arrest in Seattle: Conventional Versus Amiodarone Drug Evaluation (the CASCADE study). Am J Cardiol. 1991;67:578-84.
77. Buxton AE, Fisher JD, Josephson ME, Lee KL, Pryor DB, Prystowsky EN, et al. Prevention of sudden death in patients with coronary artery disease, the Multicenter Unsustained Tachycardia Trial (MUSTT). Prog Cardiovasc Dis. 1993;36:215-26.
78. Gafni A, Birch S. Guidelines for the adoption of new technologies: a prescription for uncontrolled growth in expenditures and how to avoid the problem. Can Med Assoc J. 1993;148:913-7.
79. Laupacis A, Feeny D, Detsky AS, Tugwell PX. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clnical and economic evaluations. Can Med Assoc J. 1992;146: 473-81
80. Laupacis A, Feeny D, Detsky AS, Tugwell PX. Tentative guidelines for using clinical and economic evaluations revisited. Can Med Assoc J. 1993; 148:927-9
81. Naylor CD, Williams JI, Basinski A, Goel V. Technology assessment and cost-effectiveness analysis: misguided guidelines? Can Med Assoc J. 1993; 748:921-4.
82. Russell LB. Some of the tough decisions required by a national health plan. Science. 1989;246:892-6.
83. Ferguson TB Jr, Ferguson CL, Crites K, Crimmins-Reda P. The additional hospital costs generated in the management of complications of pacemaker and defibrillator implantations. J Thorac Cardiovasc Surg. 1996;111:742-52.